Researchers discovered that cortactin, a cytoskeletal regulatory protein, prevents premature senescence in melanoma circulating tumor cells (CTCs) by maintaining endosomal homeostasis and controlling mTOR signaling. When cortactin was depleted, CTCs accumulated mTOR in aberrant endosomal aggregates, triggering hyperactivation that led to p53-dependent senescence through elevated mitochondrial reactive oxygen species. Clinical analysis of melanoma patients revealed that higher proportions of senescent CTCs correlated with treatment resistance and disease progression. This finding illuminates a previously unknown mechanism by which cancer cells exploit cellular aging pathways to survive in circulation before establishing metastases. The cortactin-mTOR-p53 axis represents a vulnerability that could be therapeutically exploited using sequential treatment strategies. By first depleting cortactin to force senescence, then applying senolytic drugs like anti-Bcl-xL compounds, researchers successfully eliminated persistent CTCs and suppressed metastasis in xenograft models. This approach addresses a critical gap in cancer treatment: targeting the small population of resilient circulating cells responsible for distant spread. While promising, the strategy requires validation in larger clinical trials and assessment of potential effects on normal senescent cells throughout the body.